Data completeness
3/8 — Basic
RESNIBEN (cabozantinib) by R-Pharm US is and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of ret, met, vegfr-1, -2 and -3, kit, trkb, flt-3, axl, ros1, tyro3, mer, and tie-2. Approved for hepatocellular carcinoma, renal cell carcinoma, colorectal cancer and 19 more indications.
Drug data last refreshed 2w ago
Mechanism of Action
and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis,…
Worked on RESNIBEN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.